{"id":"influsplit-tetra","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine delivers mRNA sequences encoding hemagglutinin and/or neuraminidase proteins from four influenza virus strains (typically two A strains and two B strains). Upon intramuscular injection, the mRNA is translated by host cells to produce viral antigens, which trigger both CD8+ T-cell and antibody-mediated immune responses. This approach aims to provide broader seasonal influenza protection compared to traditional inactivated or live attenuated vaccines.","oneSentence":"Influsplit® Tetra is a quadrivalent mRNA vaccine that encodes influenza virus surface antigens to stimulate immune responses against four strains of influenza.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:08.115Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention (quadrivalent coverage)"}]},"trialDetails":[{"nctId":"NCT06602024","phase":"PHASE3","title":"A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-09-16","conditions":"Seasonal Influenza","enrollment":40817},{"nctId":"NCT01439360","phase":"PHASE3","title":"An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-10-01","conditions":"Influenza","enrollment":12046},{"nctId":"NCT01878812","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-07-11","conditions":"Influenza","enrollment":117},{"nctId":"NCT02207413","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-18","conditions":"Influenza","enrollment":1886}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Influsplit® Tetra","genericName":"Influsplit® Tetra","companyName":"ModernaTX, Inc.","companyId":"modernatx-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Influsplit® Tetra is a quadrivalent mRNA vaccine that encodes influenza virus surface antigens to stimulate immune responses against four strains of influenza. Used for Seasonal influenza prevention (quadrivalent coverage).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}